-
Warren Buffett's Berkshire Hathaway Sells $116M Shares Of Dialysis Giant DaVita, Cuts Stake By 2%
Friday, February 21, 2025 - 3:00am | 543Read More...Warren Buffett‘s investment firm, Berkshire Hathaway (NYSE:BRK) (NYSE:BRK), has offloaded a 2% stake in dialysis service provider, DaVita Inc. (NYSE:DVA). The transaction, executed between February 14 and 19, is valued at around $116 million. What Happened: A Form 4 filing with the U.S....
-
Financial Crime Weekly: DaVita Agrees To Pay $34.5M For Kickbacks, Hospice Provider Doles Out $19.4M For False Claims
Friday, July 19, 2024 - 2:35pm | 863Read More...DaVita Inc. (NYSE:DVA), a Colorado-based kidney dialysis provider, agreed to pay $34.5 million for allegedly paying kickbacks to a competitor for making referrals to DaVita Rx, a former subsidiary that provided pharmacy services for dialysis patients. DaVita also allegedly paid kickbacks to...
-
Notable Insider Buys Last Week: Snowflake, Broadcom And More
Sunday, September 27, 2020 - 6:07pm | 656Read More...Insider buying can be an encouraging signal for potential investors when markets are near all-time highs. A top semiconductor maker saw a notable insider buy recently. A couple of chief executive officers picked up some shares last week. Conventional wisdom says that...
-
Barron's Picks And Pans: Goodyear, Johnson & Johnson And More
Monday, December 12, 2016 - 7:50am | 581Read More...This weekend's Barron's looks at the prospects for a leading tire manufacturer. The prospects for a healthcare giant and a dialysis pioneer are also examined. Other featured articles offer picks from a London hedge fund conference and a look at the Dow Jones Industrial Average as...
-
DaVita HealthCare's Positive Q4 Results Reignites Investor Interest
Tuesday, February 11, 2014 - 5:29pm | 500Read More...DaVita HealthCare Partners (NYSE: DVA) is soaring in after hours trading. Having issued guidance late last year, investors may not have expected much to change this afternoon. Raymond James analyst John Ransom echoed that sentiment. He told Benzinga that he thought the expectations were "pretty...
-
Adobe, Darden and Other Stocks Insiders Are Buying
Sunday, January 20, 2013 - 2:17pm | 653Read More...Insiders may sell shares for any number of reasons, but there is really only one reason insiders buy shares of a company -- they believe the stock price will move higher and they want to profit from it. Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company...
-
A Look at Fortune's Health Care Picks for 2013 (ALGN, FMS, GILD)
Sunday, December 9, 2012 - 12:17am | 631Read More...Three of Fortune's top 10 stock picks for 2013 are health care related companies. But they are not in big names in the sector, such as Johnson & Johnson (NYSE: JNJ) or Pfizer (NYSE: PFE). They were Align Technology (NASDAQ: ALGN), Fresenius Medical Care (NYSE: FMS) and Gilead Sciences (NASDAQ:...
-
Earnings Expectations for the Week of October 31
Sunday, October 30, 2011 - 11:31am | 1163Read More...Halloween and the Day of the Dead arrive this week. If analysts' forecasts are correct, there are only a few earnings reports that may scare investors. For instance, Alpha Natural Resources (NYSE: ANR) earnings are predicted to have fallen 93.1% year over year to $0.58 per share. Allstate (NYSE:...
-
UPDATE: Deutsche Bank Raises PT on DaVita to $102 (DVA)
Friday, May 13, 2011 - 7:39am | 128Read More...Deutsche Bank is out with its report today on DaVita (NYSE: DVA), raising its PT from $101 to $102. In a note to clients, Deutsche Bank writes, "As a somewhat belated follow up to Q1 results, we are introducing an updated model. While we've made some changes to assumptions which result in a 3%...
-
Deutsche Bank Raises PT On DaVita To $102
Friday, May 13, 2011 - 6:18am | 26Read More...Deutsche Bank has raised the price target on DaVita (NYSE: DVA) from $101 to $102 and maintains its Buy rating.
-
Jefferies Upgrades PT On DaVita To $101 (DVA)
Tuesday, May 3, 2011 - 8:03am | 115Read More...Jefferies has upgraded its price target on DaVita (NYSE: DVA) from $95 to $101 in a research report published today. In the report, Jefferies states, "Our $101 PT is based on a 5-year DCF analysis that assumes a WACC of 7.3% and a terminal EBITDA-MI multiple of 8.5x (in-line with historical...
-
Jefferies Raises PT On DaVita To $101
Tuesday, May 3, 2011 - 6:18am | 26Read More...Jefferies & Company has raised the price target on DaVita (NYSE: DVA) from $95 to $101 and maintains its Hold rating.
-
Jefferies Raises PT On DaVita To $95
Tuesday, April 5, 2011 - 7:31am | 26Read More...Jefferies & Company has raised the price target on DaVita (NYSE: DVA) from $81 to $95 and maintains its Hold rating.
-
Deutsche Bank Raises Price Target To $101 On DaVita
Monday, April 4, 2011 - 8:05am | 112Read More...According to Deutsche Bank, DaVita (NYSE: DVA) price target is raised to $101 and estimates are raised. Deutsche Bank reported that it is raising estimates as a result of CMS' issuance of a fix to the so-called transition budget-neutrality adjustment, which was announced late Friday April 1, 2011...
-
Deutsche Bank Raises PT On DaVita To $101
Monday, April 4, 2011 - 7:23am | 26Read More...Deutsche Bank has raised the price target on DaVita (NYSE: DVA) from $98 to $101 and maintains its Buy rating.
